Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

May 1, 2012

Date of Report (Date of Earliest Event Reported)

 

 

ALLERGAN, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   1-10269   95-1622442
(State of Incorporation)   (Commission File Number)  

(IRS Employer

Identification Number)

2525 Dupont Drive

Irvine, California 92612

(Address of Principal Executive Offices) (Zip Code)

(714) 246-4500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

Allergan, Inc. (the “Company”) held its Annual Meeting of Stockholders on May 1, 2012 (the “Annual Meeting”) and there were present in person or by proxy 270,114,143 votes, representing approximately 88.6% of the Company’s 304,714,456 total outstanding eligible votes. At the Annual Meeting, the Company’s stockholders (i) elected ten directors to the Company’s board of directors; (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2012; (iii) approved the compensation of the Company’s named executive officers; and (iv) and approved a non-binding stockholder proposal, each as more fully described below.

 

     For      Against      Abstain      Broker
Non-Votes
 
Item No. 1: Election of the following ten directors to serve for a term of office expiring at the 2013 annual meeting of stockholders and until their successors are duly elected and qualified:            

David E.I. Pyott

     243,744,825         14,188,026         305,487         11,875,805   

Herbert W. Boyer, Ph.D.

     254,000,497         4,014,536         223,305         11,875,805   

Deborah Dunsire, M.D.

     256,205,236         1,831,802         201,300         11,875,805   

Michael R. Gallagher

     250,004,353         8,007,031         226,954         11,875,805   

Dawn Hudson

     248,832,556         9,143,897         261,885         11,875,805   

Robert A. Ingram

     243,019,028         14,876,387         342,923         11,875,805   

Trevor M. Jones, Ph.D.

     255,490,135         2,415,394         332,809         11,875,805   

Louis J. Lavigne, Jr.

     255,979,928         2,004,680         253,730         11,875,805   

Russell T. Ray

     251,930,186         5,990,386         317,766         11,875,805   

Stephen J. Ryan, M.D.

     256,003,992         1,997,007         237,339         11,875,805   
Item No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2012      269,444,195         485,904         184,044         0   
Item No. 3: Advisory vote to approve the compensation of the Company’s named executive officers      230,266,686         27,156,176         815,476         11,875,805   
Item No. 4: Stockholder proposal (special stockholder meetings)      142,545,778         115,252,470         440,090         11,875,805   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ALLERGAN, INC.
Date:   May 4, 2012     By:   /s/ Matthew J. Maletta
      Name:   Matthew J. Maletta
      Title:  

Vice President,

Associate General Counsel and Secretary